Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Belantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma.
Journal: Future oncology (London, England)
Published: July 08, 2026
Linvoseltamab, a BCMA-directed CD3 T-cell engager for multiple myeloma: a patient-centric option via a response-adapted dosing regimen.
Journal: Expert review of hematology
Published: February 18, 2026
Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 01, 2025
An evaluation of linvoseltamab for treatment of relapsed/refractory multiple myeloma.
Journal: Expert opinion on biological therapy
Published: February 09, 2025
Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma.
Journal: Bone marrow transplantation
Published: October 18, 2024
The role of 1q abnormalities in multiple myeloma: Genomic insights, clinical implications, and therapeutic challenges.
Journal: Seminars in hematology
Published: September 13, 2024
Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire.
Journal: Nature communications
Published: July 18, 2024
Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials.
Journal: Oncology (Williston Park, N.Y.)
Published: June 20, 2024
Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma.
Journal: Bone marrow transplantation
Published: June 05, 2024
A novel application of XPO1 inhibition for the treatment of myelofibrosis.
Journal: Blood neoplasia
Published: February 23, 2024
Last Updated: 09/26/2026